A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India
Phase 3
Completed
NCT06060067
| Condition | Healthy Volunteers |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Takeda |
|---|
| Status | Completed |
|---|
| Enrollment | 480 participants |
|---|
| Interventions | TDV |
|---|
| Start date | Mar 29, 2024 |
|---|
| Completion date | May 5, 2025 |
|---|
| Results posted | May 29, 2026 |
|---|
Summary
The main aims of the study are to learn about side effects and a participant's immune response to Takeda's Dengue Vaccine when given twice within 3 months. Participants will receive 2 doses of their randomized treatment (vaccine or placebo). Children, teenagers and adults will receive one dose of either the vaccine or placebo on Day 1 and the second dose of either the vaccine or placebo 3 months later. Up to 4 blood samples will be taken throughout the study. During the study, participants will visit their study clinic 6 times.
Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) by Severity Within 7 Days Post-vaccination at Day 1 for Age Group Less Than 6 Years
Within 7 days post-vaccination at Day 1 · Participants
| Cohort 2: ≥4 to <6 Years Age Group: TDV | 42 Participants |
|---|
| Cohort 2: ≥4 to <6 Years Age Group: Placebo | 10 Participants |
|---|
| Cohort 2: ≥4 to <6 Years Age Group: TDV | 4 Participants |
|---|
| Cohort 2: ≥4 to <6 Years Age Group: Placebo | 4 Participants |
|---|
| Cohort 2: ≥4 to <6 Years Age Group: TDV | 0 Participants |
|---|
| Cohort 2: ≥4 to <6 Years Age Group: Placebo | 0 Participants |
|---|
Number of Participants With Solicited Local (Injection Site) AEs by Severity Within 7 Days Post-vaccination at Day 1 for Age Group 6 Years and Over
Within 7 days post-vaccination at Day 1 · Participants
| Cohort 1: ≥18 to ≤60 Years Age Group: TDV | 152 Participants |
|---|
| Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | 53 Participants |
|---|
| Cohort 2: ≥6 to <18 Years Age Group: TDV | 119 Participants |
|---|
| Cohort 2: ≥6 to <18 Years Age Group: Placebo | 42 Participants |
|---|
| Cohort 1: ≥18 to ≤60 Years Age Group: TDV | 25 Participants |
|---|
| Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | 7 Participants |
|---|
Number of Participants With Solicited Local (Injection Site) AEs by Severity Within 7 Days Post-vaccination at Day 90 for Age Group Less Than 6 Years
Within 7 days post-vaccination at Day 90 · Participants
| Cohort 2: ≥4 to <6 Years Age Group: TDV | 44 Participants |
|---|
| Cohort 2: ≥4 to <6 Years Age Group: Placebo | 14 Participants |
|---|
| Cohort 2: ≥4 to <6 Years Age Group: TDV | 2 Participants |
|---|
| Cohort 2: ≥4 to <6 Years Age Group: Placebo | 0 Participants |
|---|
| Cohort 2: ≥4 to <6 Years Age Group: TDV | 0 Participants |
|---|
| Cohort 2: ≥4 to <6 Years Age Group: Placebo | 0 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.